Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-040673
Filing Date
2025-02-28
Accepted
2025-02-28 07:22:08
Documents
18
Effectiveness Date
2025-02-28

Document Format Files

Seq Description Document Type Size
1 S-8 d926714ds8.htm S-8 31561
2 EX-5.1 d926714dex51.htm EX-5.1 8614
3 EX-23.2 d926714dex232.htm EX-23.2 1559
4 EX-FILING FEES d926714dexfilingfees.htm   iXBRL EX-FILING FEES 21419
5 GRAPHIC g926714dsp6.jpg GRAPHIC 1691
6 GRAPHIC g926714dsp6a.jpg GRAPHIC 2278
7 GRAPHIC g926714dsp6b.jpg GRAPHIC 8740
  Complete submission text file 0001193125-25-040673.txt   213064

Data Files

Seq Description Document Type Size
20 EXTRACTED XBRL INSTANCE DOCUMENT d926714dexfilingfees_htm.xml XML 6689
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285393 | Film No.: 25682583
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)